There’s a gooey time capsule in the heart of Los Angeles, left over from an era when saber-toothed cats, dire wolves, camels, ...

With Bill Belichick, the only bad publicity is no publicity. And for UNC's new football coach, the news keeps coming ad ...

Health-care companies rose, but not by as much as the broad market, as traders rotated into high-risk sectors. The Food and Drug Administration is banning the use of Red No. 3, an artificial dye ...

N-Power Medicine, backed by Merck GHI, announced the acquisition of Syapse Holdings. Samsung Biologics and LigaChem extended their ADC services deal. Publicis Worldwide merged with Leo Burnett to form ...

North Carolina continues to build their recruiting board for the 2026 class, and with them checking out Bryant it signals ...

There were some nice indicators in UNC's second-half blowout of the Cal Bears, who had their heart cut out of them.

Johnson & Johnson JNJ has initiated a rolling submission with the FDA seeking approval for TAR-200, its investigational ...

The pharma began submitting its TAR-200 bladder cancer treatment to the FDA. Elsewhere, Sarepta and Madrigal reported strong ...

An FDA application for TAR-200 to treat BCG-unresponsive high-risk non-muscle-invasive bladder cancer is under real-time ...

(RTTNews) - Johnson & Johnson (JNJ) Wednesday said it has initiated the submission of new drug application or NDA to Food and Drug Administration (FDA) for TAR-200 to treat patients with Bacillus ...

Johnson & Johnson (JNJ) said it has submitted an application to the FDA for its therapy candidate TAR-200 for the treatment of a certain type of bladder cancer. Read more here.

The New Brunswick, N.J., pharmaceutical giant said the FDA accepted the application through its Real-Time Oncology Review program, which allows for an earlier submission of topline efficacy and safety ...